It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
The results have potential to change clinical practice.NEW ORLEANS — Left atrial appendage closure in patients with atrial ...
Medpage Today on MSN
Major Trial Sours on Blanket DOAC Therapy After Successful Afib Ablation
OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...
A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...
From sleeping on staircases and bare floors to battling mosquitoes, rain, and exhaustion, relatives of patients admitted to ...
For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications ...
In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...
The Canadian Press on MSN
Blood thinners no longer needed for many with irregular heatbeats, study suggests
Those who have undergone successful corrective procedures for irregular heart beats may no longer need to commit to long-term ...
Substantial reductions in adverse cardiovascular outcomes are especially notable for this high-risk population, but ...
Lucknow: To improve brain and nerve-related treatment in UP, KGMU will soon set up a hybrid operation theatre (Hybrid OT) in ...
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...
Patients successfully treated for a common heart rhythm disorder may no longer need blood thinners, a major study has found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback